Luo Jiesi, Lin Yuyao, Shi Xiangyu, Li Guangxin, Kural Mehmet H, Anderson Christopher W, Ellis Matthew W, Riaz Muhammad, Tellides George, Niklason Laura E, Qyang Yibing
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Acta Biomater. 2021 Jan 1;119:155-168. doi: 10.1016/j.actbio.2020.10.042. Epub 2020 Oct 29.
Development of mechanically advanced tissue-engineered vascular grafts (TEVGs) from human induced pluripotent stem cell (hiPSC)-derived vascular smooth muscle cells (hiPSC-VSMCs) offers an innovative approach to replace or bypass diseased blood vessels. To move current hiPSC-TEVGs toward clinical application, it is essential to obtain hiPSC-VSMC-derived tissues under xenogeneic-free conditions, meaning without the use of any animal-derived reagents. Many approaches in VSMC differentiation of hiPSCs have been reported, although a xenogeneic-free method for generating hiPSC-VSMCs suitable for vascular tissue engineering has yet to be established. Based on our previously established standard method of xenogeneic VSMC differentiation, we have replaced all animal-derived reagents with functional counterparts of human origin and successfully derived functional xenogeneic-free hiPSC-VSMCs (XF-hiPSC-VSMCs). Next, our group developed tissue rings via cellular self-assembly from XF-hiPSC-VSMCs, which exhibited comparable mechanical strength to those developed from xenogeneic hiPSC-VSMCs. Moreover, by seeding XF-hiPSC-VSMCs onto biodegradable polyglycolic acid (PGA) scaffolds, we generated engineered vascular tissues presenting effective collagen deposition which were suitable for implantation into an immunodeficient mice model. In conclusion, our xenogeneic-free conditions for generating hiPSC-VSMCs produce cells with the comparable capacity for vascular tissue engineering as standard xenogeneic protocols, thereby moving the hiPSC-TEVG technology one step closer to safe and efficacious clinical translation.
利用人诱导多能干细胞(hiPSC)来源的血管平滑肌细胞(hiPSC-VSMC)开发机械性能先进的组织工程血管移植物(TEVG),为替代或绕过病变血管提供了一种创新方法。为了使当前的hiPSC-TEVG走向临床应用,在无外源条件下获得hiPSC-VSMC衍生组织至关重要,即不使用任何动物来源的试剂。尽管尚未建立一种无外源的方法来生成适用于血管组织工程的hiPSC-VSMC,但已有许多关于hiPSC向VSMC分化的方法报道。基于我们先前建立的异源VSMC分化标准方法,我们已将所有动物来源的试剂替换为人类来源的功能对等物,并成功获得了功能性无外源hiPSC-VSMC(XF-hiPSC-VSMC)。接下来,我们的团队通过XF-hiPSC-VSMC的细胞自组装开发了组织环,其机械强度与异源hiPSC-VSMC开发的组织环相当。此外,通过将XF-hiPSC-VSMC接种到可生物降解的聚乙醇酸(PGA)支架上,我们生成了具有有效胶原沉积的工程化血管组织,适合植入免疫缺陷小鼠模型。总之,我们用于生成hiPSC-VSMC的无外源条件所产生的细胞在血管组织工程方面的能力与标准异源方案相当,从而使hiPSC-TEVG技术向安全有效的临床转化又迈进了一步。